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Dopamine D2 receptor antagonists modulate gene transcription in the striatum. How-
ever, the molecular mechanism underlying this effect remains elusive. Here we used the
expression of Nur77, a transcription factor of the orphan nuclear receptor family, as read-
out to explore the role of dopamine, glutamate, and adenosine receptors in the effect of
a dopamine D2 antagonist in the striatum. First, we investigated D2 antagonist-induced
Nur77 mRNA in D2L receptor knockout mice. Surprisingly, deletion of the D2L receptor iso-
form did not reduce eticlopride-induced upregulation ofNur77 mRNA levels in the striatum.
Next, we tested if an ibotenic acid-induced cortical lesion could block the effect of eticlo-
pride on Nur77 expression. Cortical lesions strongly reduced eticlopride-induced striatal
upregulation of Nur77 mRNA. Then, we investigated if glutamatergic neurotransmission
could modulate eticlopride-induced Nur77 expression. A combination of a metabotropic
glutamate type 5 (mGlu5) and adenosine A2A receptor antagonists abolished eticlopride-
induced upregulation of Nur77 mRNA levels in the striatum. Direct modulation of Nur77
expression by striatal glutamate and adenosine receptors was confirmed using corti-
costriatal organotypic cultures. Taken together, these results indicate that blockade of
postsynaptic D2 receptors is not sufficient to trigger striatal transcriptional activity and
that interaction with corticostriatal presynaptic D2 receptors and subsequent activation of
postsynaptic glutamate and adenosine receptors in the striatum is required. Thus, these
results uncover an unappreciated role of presynaptic D2 heteroreceptors and support a
prominent role of glutamate in the effect of D2 antagonists.
Keywords: antipsychotic drugs, neuroleptics,Nr4a1, transcription factor, organotypic culture, glutamate receptors,
adenosine receptors, striatum
INTRODUCTION
Dopamine antagonists have been used to alleviate schizophre-
nia symptoms for more than a half-century. There is a general
agreement that in vitro binding affinity for dopamine D2 recep-
tors predicts efficacy and likelihood of causing extrapyramidal
side effects of antipsychotic drugs (Miyamoto et al., 2005). How-
ever, although all antipsychotic drugs used in clinic share the
similar pharmacological profile of being D2 antagonists (with the
exception of aripiprazole, which is a partial D2 agonist), the exact
molecular and cellular mechanisms that convey their therapeutic
and undesired effects remain elusive. A growing body of evidence
indicate that drugs targeting other neurotransmitters, such as glu-
tamate and adenosine, might also display antipsychotic activity
(Lara et al., 2006; Conn et al., 2009; Krystal et al., 2010). But,
because of the in vivo reciprocal functional relationships between
dopamine, glutamate, and adenosine receptor activities, it is dif-
ficult to pin point the specific contribution of these different
receptor subtypes.
The striatum expresses high levels of dopamine D2 receptors
and is considered as an important brain area where dopamine
and glutamate inputs are integrated to modulate psychomotor
responses. The main striatal inputs are excitatory glutamatergic
terminals coming from the cortex and thalamus, and dopamine
afferences from the substantia nigra/ventral tegmental area com-
plex. In order to process information coming from these multiple
sources, striatal cells express a large array of neurotransmitter
receptor subtypes at their surface (Gerfen and Surmeier, 2011).
Striatal cells express glutamate receptors and a functional inter-
action between the activity of dopamine D2 and metabotropic
glutamate receptors has been described. For example, block-
ade of metabotropic glutamate type 5 (mGlu5) receptor reduces
haloperidol (D2 antagonist)-induced catalepsy (Ossowska et al.,
2001). In addition, an interaction between dopamine D2, adeno-
sine A2A, and mGlu5 receptors has been demonstrated in the
striatum (Ferré et al., 2002; Kachroo et al., 2005; Cabello et al.,
2009). For example, mGlu5 receptor antagonist-induced locomo-
tor activity was abolished in postnatal forebrain-specific condi-
tional (Cre/loxP system) A2A receptor knockout mice (Kachroo
et al., 2005). In addition, using combination of bimolecular fluo-
rescence complementation and bioluminescence resonance energy
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transfer techniques, it has been shown that mGlu5, A2A, and D2
receptors can form oligomers in HEK293 cells (Cabello et al.,
2009). High-resolution immunoelectron microscopy also indi-
cated that the three receptors co-distribute within the extrasy-
naptic plasma membrane of the same dendritic spines of striatal
synapses and co-immunoprecipitation experiments demonstrated
the existence of an association of mGlu5, D2, and A2A receptors in
rat striatal homogenates (Cabello et al., 2009). Another important
contributing factor to the striatal activity is the presence of neuro-
transmitter receptors located on cortical inputs to the striatum that
regulate glutamate release. Indeed, activation of presynaptic D2
heteroreceptors located on glutamate neuron terminals (Schwarcz
et al., 1978; Wang and Pickel, 2002) modulates glutamate release
within the striatum and represents an important regulator of stri-
atal excitatory inputs (Maura et al., 1988; Cepeda et al., 2001;
Bamford et al., 2004).
Dopamine D2 receptors exist in two receptor isoforms derived
from alternative splicing of the same gene (Giros et al., 1989).
Accumulating evidence indicates that the D2 short (D2S) recep-
tor isoform is mainly associated with presynaptic activities (Khan
et al., 1998a; Usiello et al., 2000; Lindgren et al., 2003). Interestingly,
it has been shown that dopaminergic modulation of corticostri-
atal glutamate release depended upon the D2S receptors (Centonze
et al., 2004b). On the other hand, the D2 long (D2L) receptor iso-
form seems to mediate postsynaptic dopamine receptor functions
(Khan et al., 1998a; Usiello et al., 2000; Lindgren et al., 2003).
Modulation of gene transcription within neurons rapidly leads
to protein synthesis and subsequent cellular adaptation. It is well
documented that typical antipsychotic drugs rapidly induce genes
like c-fos, Zif268, and Nur77 (NGFI-B, Nr4a1; Herrera and Robert-
son, 1996; Herdegen and Leah, 1998; Lévesque and Rouillard,
2007). Nur77 is a transcription factor of the nuclear receptor
family that is rapidly induced after treatment with typical antipsy-
chotic drugs (D2 antagonists; Beaudry et al., 2000; Maheux et al.,
2005). Previous reports from our laboratory indicate that Nur77 is
involved in gene expression as well as in abnormal motor behaviors
following exposure to a typical antipsychotic drug (for a review see,
Lévesque and Rouillard, 2007). For example, haloperidol-induced
striatal neuropeptides enkephalin and neurotensin mRNA expres-
sion is strongly impaired in Nur77 knockout mice (Ethier et al.,
2004a), while these mice display exacerbated haloperidol-induced
vacuous chewing movements (similar to tardive dyskinesia; Ethier
et al., 2004b). However, the exact contribution of glutamate,
adenosine, and dopamine D2S and D2L receptors in the regulation
of striatal gene expression remains to be clarified. In the present
study, using Nur77 mRNA expression as readout, we show that
D2 antagonist-induced transcriptional activity in the striatum is
mediated by interaction of the drug with presynaptic D2S het-
eroreceptors located at corticostriatal terminals and subsequent




For pharmacological experiments, adult male wild type C57BL/6
mice (Charles River, St-Constant, QC, Canada) and mice lacking
dopamine D2L receptors [D2L receptor knockouts, D2L(−/−)] and
their littermates (Usiello et al., 2000) were used. All mice weighted
20–25 g and were housed five per cage in a temperature-controlled
environment maintained under a 12-h light/dark cycle with ad libi-
tum access to food and water. For experiments involving ibotenic
acid lesions, we used male Sprague–Dawley rats (Charles River,
St-Constant, QC, USA) weighing 280–320 g. Experimental pro-
cedures, including means to minimize discomfort, were reviewed
and approved by the institutional Animal Ethics Committee of
the Université de Montréal and were done in accordance with
the Canadian Council on Animal Care guidelines for use of
experimental animals.
DRUGS AND TREATMENTS
The selective dopamine D2/D3 receptor antagonist eticlopride,
cannabinoid CB1 receptor antagonist 1-(2,4-dichlorophenyl)-5-
(4-iodophenyl)-4-methyl-N -1-piperidinyl-1H-pyrazole-3-carbox
amide (AM251), muscarinic antagonist scopolamine, and selec-
tive adenosine A2A antagonist SCH 58261 were purchased from
Sigma–Aldrich (St. Louis, MO, USA). The selective mGlu5 antago-
nist 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP),
mGlu1/5 agonist (RS)-3,5-Dihydroxyphenylglycine (DHPG),
selective mGlu5 agonist (RS)-2-Chloro-5-hydroxyphenylglycine
sodium salt (CHPG), selective A2A agonist 4-[2-[[6-Amino-
9-(N -ethyl-β-d-ribofuranuronamidosyl)-9H-purin-2-yl]amino]
ethyl]benzene propanoic acid hydrochloride (CGS 21680), and
excitatory amino acid transporters 1-2 (EAAT1-2) blocker (3S)-
3-[[3-[[4-(Trifluoromethyl)benzoyl] amino]phenyl]methoxy]-l-
aspartic acid (TBOA) were purchased from Tocris Bioscience
(Avonmouth, UK). Non-competitive NMDA antagonists phency-
clidine (PCP) and MK-801 were obtained from Sigma–Aldrich
through a restricted importation permit. PCP analogs N -[1-
(2-benzo(β)thiophenyl)cyclohexyl]piperidine (BTCP) and N -[1-
(2-thiophenyl)cyclohexyl]piperidine (TCP) were obtained as a
gift from Dr. J. M. Kamenka and the National Institute of
Mental Health Chemical Synthesis Program (Rouillard et al.,
1990).
First, we compared the effect of vehicle (NaCl 0.9%) and eticlo-
pride (1 mg/kg) on striatal Nur77 mRNA expression in wild type
[D2L(+ /+)] and D2L(−/−) mice in order to assess the contribu-
tion of D2S and D2L receptor isoforms in the effect of the D2 antag-
onist. We used eticlopride, a highly selective D2/D3 receptor antag-
onist, because typical antipsychotic drugs used in clinics display
a wider pharmacological profile, which could further complicate
data interpretation. Note that eticlopride displays activities similar
to typical antipsychotic drugs, but it is not used in clinic because of
its poor pharmacokinetic properties (Martelle and Nader, 2008).
Secondly, we assessed the effect of glutamatergic drugs on Nur77
gene transcription. We acutely treated (0.25 ml, i.p.) five differ-
ent groups of wild type mice (N = 5) as follows: (a) vehicle (NaCl
0.9%); (b) MK-801 (non-competitive NMDA receptor antagonist,
0.75 mg/kg); (c) PCP (5 mg/kg); (d) BTCP (16 mg/kg); and (e)
TCP (0.75 mg/kg). Then, lower doses of MK-801 were used alone
or in combination with eticlopride. Groups of mice were formed as
follows: (a) vehicle (NaCl 0.9%; N = 6); (b) eticlopride (1 mg/kg;
N = 5); (c) MK-801 (0.3 mg/kg; N = 5); (d) MK-801 (0.03 mg/kg;
N = 5); (e) eticlopride (1 mg/kg)+MK-801 (0.3 mg/kg); (f) eti-
clopride (1 mg/kg)+MK-801 (0.03 mg/kg). MK-801 was injected
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15 min before eticlopride. In the third experiment, involvement
of mGlu5 and A2A receptor drugs on eticlopride-induced Nur77
upregulation was investigated. Animals were distributed into
eight groups and treated as follows: (a) vehicles (NaCl 0.9 and
3% DMSO, 8% PEG600 in sterile water); (b) MPEP (mGlu5
antagonist, 10 mg/kg); (c) SCH58261 (A2A antagonist, 5 mg/kg);
(d) MPEP + SCH58261; (e) eticlopride (dopamine D2 antag-
onist, 1 mg/kg); (f) eticlopride (1 mg/kg)+MPEP (10 mg/kg);
(g) eticlopride (1 mg/kg)+ SCH58261 (5 mg/kg); (h) eticlopride
(1 mg/kg)+MPEP+ SCH58261 (N = 5 per group). MPEP and
SCH58261 were administered 30 min before the dopamine antag-
onist. A similar paradigm was used to investigate the effect of
the CB1 antagonist AM251 (5 mg/kg, i.p.) and muscarinic m1-4
antagonist scopolamine (2.5 mg/kg, i.p.) on eticlopride-induced
Nur77 expression. All the drug doses used were chosen based on
previous studies using similar paradigms; eticlopride (Keefe and
Adams, 1998; Pozzi et al., 2003; Bourhis et al., 2008), ionotropic
glutamatergic drugs (Rouillard et al., 1990; Keefe and Adams, 1998;
Chartoff et al., 1999), MPEP (Choe et al., 2002; Parelkar and Wang,
2004), SCH58261 (Pollack and Fink, 1995; Pinna et al., 1999),
AM251 (Xi et al., 2006; Rubino et al., 2007), and scopolamine (Guo
et al., 1992; Wang and McGinty, 1996). For all treatments, mice
were sacrificed by decapitation 60 min after the last drug injection
under CO2 anesthesia. Brains were rapidly removed, immediately
immersed into cold 2-methylbutane (−40ºC) for a few seconds
and kept frozen at−80ºC until used.
IN SITU HYBRIDIZATION
Probe preparation and in situ hybridization of Nur77 mRNA
on brain slices were performed as previously reported (Beaudry
et al., 2000; St-Hilaire et al., 2003; Maheux et al., 2005).
Briefly, the Nur77 single-stranded riboprobe was synthesized
and labeled using Promega riboprobe kit (Promega, Madison,
WI, USA), [35S]UTP (PerkinElmer Life and Analytical Sci-
ences, Woodbridge, ON, Canada), and the RNA polymerase
T3. In situ hybridization of the riboprobe with cryostat coro-
nal brain sections (12µm) mounted on Snowcoat X-tra slides
(Surgipath, Winnipeg, MA, Canada) was done at 58˚C overnight
in a standard hybridization buffer containing 50% formamide.
Brain sections were then apposed against BiomaxMR radioac-
tive sensitive films (Eastman Kodak, New Haven, CT, USA) for
2 days.
QUANTIFICATION AND STATISTICAL ANALYSIS
Levels of autoradiographic labeling on films were quantified
by computerized densitometry as previously described (Beaudry
et al., 2000; St-Hilaire et al., 2003; Maheux et al., 2005). Opti-
cal density of the autoradiograms was translated in nCi/g of
tissue using [14C]-radioactivity standards (ARC 146A-14C stan-
dards, American Radiolabeled Chemicals Inc., St. Louis, MO,
USA). Nur77 mRNA levels were measured in the dorsomedial
(StDM), dorsolateral (StDL), ventromedial (StVM), and ventro-
lateral (StVL) portions of the striatum, and the nucleus accumbens
shell (AcSh) and core (AcC). The average level of labeling for each
area was calculated from three to four adjacent brain sections of
the same animal. Background intensity was subtracted from every
measurement.
All data are expressed as group mean± SEM and statisti-
cal analysis were performed using GraphPad Prism version 5.0
(GraphPad Software Inc.,San Diego,CA,USA). Statistical compar-
isons between groups were obtained by using a one-way analysis of
variance and a Bartlett’s test for equal variance. When the Bartlett’s
test showed significant differences between variance, the log, or
square root of data were used in the analysis. One-way analyses of
variance were followed by a Tukey’s multiple comparison test as a
post hoc test when appropriate.
DOPAMINE D2 RECEPTOR AUTORADIOGRAPHY
Brain sections were pre-incubated in a 50 mM Tris-HCl buffer,
pH 7.4, containing 120 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 5.7 mM ascorbic acid, and 10µM hydroxyquinoline for
15 min. The slides were then incubated for 1 h a room temperature
in the same buffer containing 0.2 nM [125I]iodosulpride (Martres
et al., 1985). Non-specific binding was evaluated in the presence
of 2µM raclopride. After 2 min rinses in ice-cold buffer, sections
were dipped for 10 s in cold water, dried, and apposed to BioMax
film. Autoradiograms were generated after an exposure time of
24 h.
IBOTENIC ACID CORTICAL LESIONS
Rats were anesthetized with isoflurane (2.5–3.5%, O2 0.6 L/min)
and mounted on a stereotaxic apparatus. The surface of cranium
was exposed and the bone and dura above the left or right sen-
sorimotor cortex was removed. A needle (300µm in diameter)
containing 5µg/µl of ibotenic acid, or its vehicle, was inserted
into the cortex at five anterior-posterior (0.5 mm apart) and 2–
4 medial-lateral sites using the following flat skull coordinates:
between 0.5 posterior and 1.5 mm anterior to Bregma; 1.4–3.3 mm
lateral to the sagittal line, and 1.2–2.2 mm below the surface of the
cortex. At each site, the needle was lowered to 2.2 mm below the
cortex and a volume of 0.15µl solution was injected over a minute;
two (three for the most lateral and anterior sites) similar injec-
tions were made 0.5 and 1.0 mm above. The solution was injected
using a microinfusion pump to activate a Hamilton microsyringe
connected to the injection needle by polyethylene tubing. Simi-
lar saline injections were performed in sham animals. Ten days
after surgery, animals were injected with eticlopride (1 mg/kg, i.p.)
or saline and returned to their home cage. Sixty minutes after
the injection, they were anesthetized with isoflurane (3.5%, O2
0.6 L/min) and killed by decapitation. The brains were quickly
removed dipped in cold 2-methylbutane and stored at−80˚C.
CORTICOSTRIATAL ORGANOTYPIC SLICES
Corticostriatal organotypic slice cultures were prepared from 4–
5 days old mice using the methods of Stoppini et al. (1991) and
Stahl et al. (2009) with minor modifications (Stoppini et al.,
1991; Stahl et al., 2009). Briefly, mouse brains were extracted
and immerged in complete Hank’s buffer solution supplemented
with glucose (5.6 mM) and sucrose (27.8 mM). Coronal 400µm
slices were cut using a McIlwain tissue chopper (Havard Appa-
ratus, St. Laurent, QC, USA). Slices containing the striatum were
transferred on Millicell filter inserts (0.4µm; Millipore, Fisher sci-
entific, Whitby, ON, USA) placed into a six-well plate filled with
1 ml of neurobasal medium containing 10% FBS, 1× N-2 supple-
ment, 1× glutamine, 1× antibio-antimyc, and 0.6% glucose and
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maintained in culture for 3 days. Slices were then serum deprived
for 14 h before pharmacological treatments. Drugs such as TBOA,
DHPG, CHPG, and CGS 21680 were applied for 1 h directly to the
culture medium. MPEP or quinpirole were applied 15 min prior
subsequent treatments. Striata were removed using a glass Pasteur
pipette as a tissue punches.
Striatal tissue samples were expelled directly in Trizol
reagent for RNA extraction (Sigma–Aldrich, St. Louis, MO,
USA). Reverse transcriptase reactions of 2µg RNA were per-
formed in a final volume of 20µl using the High Capac-
ity cDNA Reverse Transcription Kit with random primers
(Applied Biosystems, Streetsville, ON, USA). Complementary
DNA samples (1.5µl) were used for SYBR green qPCR ampli-
fication of Nur77 (Nr4a1; NM_010444.2) using Fast SYBR
Green Master Mix (Applied Biosystems, Streetsville, ON, USA).
Gene expression level for endogenous controls was determined
using pre-validated Taqman Gene Expression Assays (Applied
Biosystems, Streetsville, ON, USA). Four endogenous controls
[glyceraldehyde-3-phosphate (GAPDH), hypoxanthine guanine
phosphoribosyl transferase (HPRT1), β-actin, ACTB, and TATA
binding protein (TBP)] were first assessed to determine which
ones had the more stable expression in our experimental condi-
tions. Further analysis of each sample was controlled using both
GAPDH (NM_008084.2) and HPRT1 (NM_013556). The ABI
PRISM® 7900HT Sequence Detection System (Applied Biosys-
tems, Streetsville, ON, USA) was used to detect amplification
levels. All reactions were run in triplicate and average values of
cycle thresholds (CTs) were used for quantification. The relative
quantification of target genes was determined using the 44CT
method.
RESULTS
DOPAMINE D2L RECEPTOR KNOCKOUT DOES NOT PREVENT
ETICLOPRIDE-INDUCED NUR77 EXPRESSION IN THE STRIATUM
We first investigated the contribution of D2S and D2L receptors
in the modulation of Nur77 mRNA expression in the striatum
by comparing basal and eticlopride-induced Nur77 mRNA lev-
els in wild type (+/+) and D2L knockout (−/−) mice (Usiello
et al., 2000; Lindgren et al., 2003). D2L(−/−) mice displayed a
significant reduction in basal Nur77 mRNA levels in the dor-
somedial striatum, but basal transcript levels were unchanged
in all other striatal subterritories, as compared with their wild
type littermates (Figure 1). As expected, administration of eti-
clopride in wild type mice led to a strong increase of Nur77
transcript levels (Figure 1). Surprisingly, this modulation was
still present in D2L mutant mice (Figure 1), and was even sig-
nificantly stronger when compared to their wild type littermates
in most striatal subterritories (Figure 1). These data indicate
FIGURE 1 | Eticlopride induces Nur77 mRNA levels in D2L knockout
mice. Nur77 mRNA levels (expressed as% of control) were measured in
(A) dorsomedial (StDM), (B) dorsolateral (StDL), (C) ventromedial (StVM),
(D) ventrolateral (StVL) portions of the striatum in dopamine D2 long
receptor isoform knockout [D2L(−/−)] mice and their wild type littermates
[D2L(+ /+)]. Histograms represent mean±SEM (***p<0.001 vs. vehicle
(VEH) of the same strain, #p<0.05 and ###p<0.001 vs. eticlopride
(ETI)-treated wild type [D2L(+ /+)] mice, N = 8 per group). Insets
represent drawings of specific striatal areas (in gray) used for
quantification.
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that D2L receptors might not play an important role in the
effect of eticlopride-induced Nur77 expression in the striatal
tissue.
CORTICAL LESIONS ABOLISH ETICLOPRIDE-INDUCED Nur77
EXPRESSION IN TARGETED STRIATAL SUBTERRITORRIES
In order to investigate whether integrity of the corticostriatal
pathway, and therefore involvement of presynaptic D2 heterore-
ceptors in eticlopride-induced Nur77 mRNA in the striatum,
we proceeded to unilateral lesions of corticostriatal fibers using
intra cortical injections of ibotenic acid. Ibotenic acid injections
led to the lesion of most cortical neurons located in the pri-
mary motor cortex (M1) and affected all layers of the cortex.
In some individuals, the lesion extended to the primary senso-
rimotor cortex (Figures 2A–C). Nissl staining (data not shown)
and [125I] iodosulpride specific binding to dopamine D2 recep-
tors showed that underlying subcortical regions were left intact
(compared Figures 2B,C). As expected, eticlopride-induced a
strong increase in Nur77 mRNA levels in control animals bear-
ing a sham lesion (Figure 2D). On the other hand, unilateral
cortical lesion almost totally prevented eticlopride-induced upreg-
ulation of Nur77 mRNA levels in the ipsilateral dorsal striatum
(Figure 2D). Eticlopride-induced striatal Nur77 mRNA levels
were comparable to sham-lesioned animals in the contralateral
side (Figure 2D). These data clearly indicate that the integrity of
corticostriatal inputs is necessary for the upregulation of Nur77
mRNA levels by the D2 antagonist in these striatal subterritories.
ETICLOPRIDE-INDUCED Nur77 EXPRESSION IS REDUCED BY
GLUTAMATE mGLU5 AND ADENOSINE A2A RECEPTOR ANTAGONISTS
We then investigated if glutamate receptors located on postsynap-
tic striatal medium spiny neurons might contribute to the effect of
the D2 antagonist. To test this hypothesis, we combined the admin-
istration of eticlopride with ionotropic or metabotropic gluta-
mate receptor antagonists. Although the modulation of Nur77
mRNA levels by dopamine D2 antagonists has been previously
described (Beaudry et al., 2000; Werme et al., 2000; Maheux
et al., 2005), modulation of this transcription factor by glutamate
receptors remains largely unexplored. Thus, we first evaluated the
effect of NMDA antagonists on striatal Nur77 mRNA levels in
wild type mice. Both MK-801 (0.75 mg/kg) and PCP (5 mg/kg)
strongly reduced basal Nur77 mRNA levels in the striatal com-
plex (Figure 3). We also used two PCP analogs to confirm the
role of NMDA receptors in the effect of PCP. TCP is a PCP
analog, which display a stronger affinity for the PCP site on the
NMDA receptor than PCP itself, whereas BTCP is a PCP analog
FIGURE 2 | Ibotenic acid lesions of the cortex prevent
eticlopride-induced Nur77 mRNA levels. (A) Schematic representation
showing the average extent of ibotenic acid lesions in the primary motor
cortex (M1). The darker gray area represents the biggest lesions obtained,
whereas lighter gray area shows the smallest ones. The shaded area
indicates the region used for quantification of Nur77 mRNA levels in the
striatum. Similar quantifications were performed in the unlesioned side
(contralateral). (B) Representative autoradioagram of [125I]iodosulpride
specific binding at dopamine D2 receptors on a coronal slice showing that
the lesions remain circumscribed in the cortex. Dash lines depict the
position of the corpus callosum identified on an adjacent section after
Nissl staining (not shown). (C) Representative autoradiogram showing
in situ hybridization of the Nur77 mRNA after eticlopride (ETI)
administration. (D) Quantification of striatal Nur77 mRNA levels in the
ipsilateral (IPSI) and contralateral (CONTRA) sides of the lesion in animals
treated with saline or eticlopride (ETI) and bearing a sham or an ibotenic
acid-induced lesion. Data are expressed in µCi/g of tissue. Histogram bars
represent means±SEM (N =5, **p<0.01 and ***p< 0.001 vs. same
side control (Sham-Saline); ###p<0.001 vs. IPSI side of Ibotenic-ETI
group and ♦♦♦p<0.001 vs. CONTRA side of Ibotenic-ETI group).
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characterized by a higher affinity for the dopamine transporter
(Rouillard et al., 1990). A dose equivalent of BTCP produced
a strong increase in Nur77 expression (Figure 3). This effect is
consistent with the BTCP psychostimulant-like property, since
it has been previously shown that psychostimulants increased
Nur77 mRNA levels (Bäckman and Morales, 2002; Bhardwaj
et al., 2003). A PCP dose equivalent of TCP based on their
affinity for the PCP site did not induce Nur77 mRNA levels,
but rather tended to reduce it (however, it did not reach sig-
nificance). Thus, we may conclude from these experiments that
basal striatal Nur77 expression is under a tonic control by NMDA
receptors.
In the next step, we investigated the role of NMDA receptors
into the upregulation of Nur77 mRNA expression induced by
the D2 antagonist eticlopride. Since the initial dose of MK-801
(0.75 mg/kg) induced a strong reduction of basal Nur77 expres-
sion (Figure 3), which could be mixed up with the putative effect
of NMDA on eticlopride-induced Nur77 expression, we investi-
gated two lower doses of MK-801 (0.03 and 0.3 mg/kg) alone or
in combination with eticlopride (Figures 4A–D). At these concen-
trations, MK-801 was still able to reduce basal Nur77 levels, but
to a lesser extent (Figures 4A–D). However, both MK-801 doses
did not alter eticlopride-induced Nur77 expression in lateral stri-
atal subterritories (Figures 4B,D) and the lower dose of MK-801
(0.03 mg/kg) also remained without effect in medial portions of
the striatum (Figures 4A,C). Note that a similar low dose of MK-
801 can modulate c-fos mRNA levels in the brainstem, as well as
to reduce reward threshold induced by electrical self-stimulation
of the ventral tegmental area (Hattori et al., 2004; Clements and
Greenshaw, 2005), indicating that this dose is effective.
FIGURE 3 | NMDA antagonists reduced basal Nur77 expression. Levels
of Nur77 mRNA (expressed as% of control) were measured in the
ventrolateral portion of the striatum after treatment with vehicle (VEH),
MK-801 (0.75 mg/kg, i.p.), PCP (5 mg/kg, i.p.), TCP (0.75 mg/kg, i.p.), or
BTCP (16 mg/kg, i.p.). Histograms represent mean±SEM (**p<0.01 vs.
VEH, N = 5 per group). Inset: representative autoradiograms showing
Nur77 mRNA levels in a left hemi-brain from the VEH group and a right
hemi-brain from the PCP group.
Since these results suggested a modest contribution of NMDA
receptors in eticlopride-induced Nur77 mRNA levels in the stria-
tum, we investigated the role of the metabotropic glutamate
mGlu5 receptor and its partner, the adenosine A2A receptor
(Figures 4E–I). Administration of MPEP (mGlu5 antagonist)
or SCH58261 (A2A antagonist) alone had no effect on Nur77
mRNA expression in the brain areas analyzed (Table 1). When co-
administered with eticlopride, SCH58261 had no significant effect
on the upregulation of Nur77 mRNA expression (Figures 4E–I).
Selective blockade of mGlu5 receptor with MPEP tended to reduce
eticlopride-induced Nur77 mRNA levels, but this effect reached
significance only in the dorsolateral portion of the striatum
(Figure 4G). Interestingly, co-administration of both MPEP and
SCH58261 strongly reduced eticlopride-induced Nur77 mRNA
levels in all striatal subterritories, restoring Nur77 mRNA levels
back to baseline (Figures 4E–I).
To complement the pharmacological characterization of the
dopamine D2 receptor antagonist effect, we also investigated the
contribution of cannabinoid and muscarinic drugs in the mod-
ulation of striatal Nur77 mRNA levels induced by eticlopride.
Systemic injections of AM251, a CB1 receptor antagonist or scopo-
lamine, a muscarinic m1-4 receptor antagonist, alone did not
modulate Nur77 mRNA levels in the ventrolateral portion of
the striatum (Figure 5). Co-administration of AM251 or scopo-
lamine with the D2 antagonist did not reduce eticlopride-induced
Nur77 expression in the ventrolateral portion of the striatum
(Figure 5). In fact, scopolamine significantly further increased
eticlopride-induced Nur77 expression (Figure 5).
mGLU5 RECEPTORS, BUT NOT D2 RECEPTORS, MODULATE Nur77
EXPRESSION IN STRIATAL ORGANOTYPIC CULTURES
To directly demonstrate the contribution of mGlu5 and adeno-
sine A2A receptor subtypes to the modulation of Nur77 mRNA
expression, we tested whether an increase of glutamatergic neuro-
transmission or mGlu5 and A2A receptor activation can modulate
Nur77 mRNA levels in corticostriatal organotypic slices in culture.
To this end, we used TBOA, which is a high affinity blocker of
glial excitatory amino acid transporters 1 and 2 (EAAT1-2), which
has been shown to increase glutamate concentration in acute slice
preparations (Beurrier et al., 2009). TBOA alone produced a nice
and strong dose-dependent Nur77 mRNA induction (Figure 6A).
Pre-treatment of organotypic cultures with MPEP, a selective
mGlu5 receptor antagonist, significantly reduced the effect of
the low dose of TBOA on Nur77 mRNA induction, confirm-
ing the important role of mGlu5 receptor in the induction of
Nur77 gene transcription by glutamate (Figure 6B). We there-
fore tested direct activation of mGlu5 receptor in organotypic
corticostriatal slices. Exposition to DHPG, a mGlu1/5 agonist,
significantly increased Nur77 mRNA expression in the striatum
by approximately fivefold (Figure 6C). This effect was selective
for mGlu5 receptors since co-administration of MPEP led to a
complete blockade of DHPG-induced Nur77 mRNA upregula-
tion (Figure 6C). Additionally, activation of mGlu5 receptor with
a more specific agonist (CHPG) also led to a strong increase
of Nur77 mRNA levels (Figure 6D). As previously observed
in vivo, this effect can be potentiated by a concomitant activation
of A2A receptors with CGS21680 (Figure 6D). Direct exposure
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FIGURE 4 | Blockade of mGlu5 and A2A receptors abolishes
eticlopride-induced upregulation of Nur77 mRNA expression. Modulation
of basal and eticlopride-induced Nur77 mRNA levels by the NMDA antagonist
MK-801 (0.03 or 0.3 mg/kg) was measured in (A) dorsomedial (StDM), (B)
dorsolateral (StDL), (C) ventromedial (StVM), (D) ventrolateral (StVL) portions
of the striatum. Insets represent drawings of specific striatal areas (in gray)
used for quantifications. Basal Nur77 mRNA levels in respective striatal
subterritories of untreated animals were set to 100% and are indicated as
dash lines. Histograms represent mean±SEM of animals treated with
MK-801 (0.3 or 0.03 mg/kg) alone or eticlopride- and MK-801 (MK)-treated
animals (*p<0.05, **p<0.01, and ***p< 0.001 vs. vehicle (VEH); #p<0.05
and ###p<0.001 vs. eticlopride, N =5 per group). (E) Representative
autoradiograms showing Nur77 mRNA levels following drug administrations.
Inhibitions of eticlopride-induced Nur77 expression (expressed as% of
control, dash lines) by the vehicle (VEH), SCH58261 (SCH), MPEP, or
SCH+MPEP were measured in (F) dorsomedial (StDM), (G) dorsolateral
(StDL), (H) ventromedial (StVM), (I) ventrolateral (StVL) portions of the
striatum. Nur77 mRNA levels in animal treated with VEH, MPEP, SCH58261,
or MPEP+SCH58261 alone can be found inTable 1. Histograms represent
mean±SEM of eticlopride-treated groups (**p<0.01 and ***p<0.001 vs.
control; #p<0.05, ##p<0.01, and ###p<0.001 vs. eticlopride alone (VEH);
♦p<0.05 and ♦♦p<0.01 vs. MPEP+eticlopride, N =5 per group).
Table 1 | Nur77 mRNA levels following vehicle, MPEP, and SCH58261 in striatal subterritories.
Brain areas Nur77 mRNA levels (% of control)
VEH MPEP SCH58261 MPEP+SCH58261
StDM 100±15 86±20 83±7 83±4
StDL 100±12 105±22 93±18 87±4
StVM 100±14 155±21 77±29 129±22
StVL 100±16 119±26 75±50 108±35
AcSh 100±10 88±36 73±5 107±16
AcC 100±11 141±13 98±14 106±9
AcC, nucleus accumbens core; AcSh, nucleus accumbens shell; StDM, dorsomedial striatum; StDL, dorsolateral striatum; StVM, ventromedial striatum; StVL,
ventrolateral striatum; VEH, vehicle.
of corticostriatal organotypic slices to eticlopride or quinpirole
(dopamine D2 agonist) alone or in combination with TBOA did
not modulate Nur77 mRNA levels (Figures 6E–G). In addition,
both D2 agonist and antagonist drugs were not able to modu-
late mGlu5/A2A agonist-induced striatal Nur77 mRNA levels in
organotypic slice preparations (Figure 6H). These results sug-
gest that postsynaptic D2 receptors do not significantly contribute
to striatal transcriptional activity in the present experimental
conditions.
DISCUSSION
Our results indicate that the modulation of striatal Nur77 mRNA
expression by a dopamine D2 antagonist depends on the integrity
of the corticostriatal pathway and postsynaptic striatal mGlu5 and
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FIGURE 5 | Cannabinoid and muscarinic receptor antagonists did not
reduce eticlopride-induced Nur77 mRNA levels in the striatum.
(A) Groups of mice were treated with, either saline 0.9% (VEH, N = 5),
eticlopride (ETI, 1 mg/kg, N =5), CB1 antagonist AM251 (5 mg/kg, N =5),
or a combination of ETI and AM251. (B) Groups of mice were treated with,
either VEH (N =5), ETI (1 mg/kg, N = 5), scopolamine (SCO, 2.5 mg/kg,
N = 5), or a combination of SCO and ETI. AM251 and SCO were
administered 15 min prior ETI. Histograms represent means±SEM. Nur77
mRNA levels are expressed in% of control (VEH) in the ventrolateral
portion of the striatum (***p<0.001 vs. VEH and ##p< 0.01 vs. ETI
alone). Similar results were obtained in the other striatal subterritories
(data not shown).
A2A receptors activation (see Figure 7 for a proposed model).
Thus, presynaptic modulation of glutamate neurotransmission is
required in the modulation of striatal transcriptional activity fol-
lowing the administration of a selective D2 receptor antagonist
(see Figure 7).
It is generally recognized that blockade of striatal postsynaptic
D2 receptors is associated with antipsychotic drug activity in the
striatum. Thus, the preservation of the effect of the D2 antagonist
on Nur77 mRNA expression in the D2L(−/−) mice was somewhat
surprising. In the D2L(−/−) mouse, the lack of exon 6, specific for
the D2L isoform, results in the conversion of all dopamine D2
receptor transcripts into D2S receptors (Usiello et al., 2000; Lind-
gren et al., 2003; Centonze et al., 2004b). Our results clearly show
that the D2 receptor antagonist could still induce strong activa-
tion of Nur77 gene transcription in D2L mutant mice. Therefore,
ectopic postsynaptic D2S expression might have fulfilled D2L activ-
ity in D2L(−/−) mice. However, this possibility is unlikely because
postsynaptic activity of dopamine, such as modulation of DARPP-
32 phosphorylation in the striatum, is hampered in this mouse
strain (Lindgren et al., 2003). A better understanding of the dif-
ference between the two isoforms subcellular expression will be
required to better explain this observation. Since D2L receptors
are mainly associated with postsynaptic effect of dopamine (Khan
et al., 1998b; Usiello et al., 2000; Lindgren et al., 2003), it suggests
that a presynaptic event might be needed for eticlopride-induced
gene transcription in the striatum.
Dopamine D2 receptors can modulate glutamate signaling
through both pre- and postsynaptic mechanisms. These receptors
can be found on cortical inputs from the corticostriatal pathway
(presynaptic D2 heteroreceptors), where they can modulate glu-
tamate release in the striatum (Bamford et al., 2004; Higley and
Sabatini, 2010). The present results show that the integrity of the
corticostriatal pathway and therefore the presence of presynap-
tic D2 heteroreceptors are essential for eticlopride-induced striatal
gene expression. We demonstrated this by performing extensive
lesions of motor cortex by means of intra cortical administration
of ibotenic acid. Such lesions have been documented to decrease
the role of excitatory amino acid transmission in targeted sub-
cortical areas (Cromwell and Levine, 1996; Garcia et al., 2010). In
accordance, the striatal areas altered by the present cortex lesions
were restricted to striatal subterritorries (Voorn et al., 2004; Gar-
cia et al., 2010). This suggests that the corticostriatal pathway is of
the upmost importance in mediating D2 antagonist regulation of
transcription in those striatal areas.
These results fall in line with increasing evidence showing the
importance of glutamate-dopamine interplay in striatal functions.
Interestingly, the present results indicate that ionotropic NMDA
receptors are minimally involved in the upregulation of striatal
gene transcription by the D2 antagonist, but rather support an
important role for the metabotropic mGlu5 receptor subtype.
Noteworthy, a number of reports have shown an important inter-
action between dopamine D2 and mGlu5 receptors along with
adenosine A2A receptors. First, an intracellular signaling synergy
has been observed between mGlu5 and adenosine A2A receptors
in the striatum (Nishi et al., 2003). It has been shown also that
co-activation of these receptors can induce c-fos expression in a
synergistic manner in the nucleus accumbens and dual blockade
of these receptors leads to a synergistic activation of locomotor
activity (Ferré et al., 2002; Kachroo et al., 2005). Our data (both
in vivo and in vitro) reveal another system in which activation of
mGlu5 and A2A produces an additive response. Although previous
observations support a direct postsynaptic interaction between D2,
A2A, and mGlu5 receptors (Ferré et al., 2002; Kachroo et al., 2005;
Bertran-Gonzalez et al., 2009), the present observations suggest
that D2-A2A-mGlu5 interaction may also occur indirectly from the
activity of a presynaptic D2 receptor (see Figure 7). Presynaptic
modulation of glutamate neurotransmission by a D2 antagonist
is also consistent with previous studies showing that acute and
chronic administration of typical antipsychotic drugs, including
haloperidol and eticlopride, increase glutamate concentration in
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FIGURE 6 | Striatal Nur77 expression is induced by metabotropic
glutamate and adenosine receptors in corticostriatal organotypic
slice cultures. Nur77 mRNA levels were measured in striatal tissue
punches using quantitative real-time RT-PCR from corticostriatal
organotypic cultures treated with (A) vehicle (VEH) or increasing doses of
TBOA, a glutamate reuptake inhibitor (N =3; *p<0.05 vs. VEH group),
(B) VEH, TBOA, MPEP (a mGlu5 receptor antagonist) alone, or
TBOA+MPEP (N =5–6; ***p<0.001 vs. VEH; ###p<0.001 vs. TBOA
group), (C) VEH, MPEP, DHPG (a mGlu1/5 receptor agonist), or
MPEP+DHPG (N =5; *p<0.05 vs. VEH; #p<0.05 vs. DHPG group),
(D) VEH, CGS21680 (CGS, a adenosine A2A receptor agonist), CHPG (a
selective mGlu5 receptor agonist), and CGS+CHPG (N =5;
***p<0.001 vs. VEH; # p<0.05 vs. CHPG group), (E) VEH or increasing
doses of the D2 receptor antagonist eticlopride (ETI; N = 6), (F) VEH,
quinpirole (QUIN, a dopamine D2 receptor agonist), ETI, TBOA,
TBOA+QUIN (N =6–9; ***p< 0.001 vs. VEH group), (G) VEH, ETI,
TBOA, and TBOA+ETI (N =3; ***p<0.001 vs. VEH group), and (H) VEH,
CHPG+CGS, CHPG+CGS+QUIN, and CGS+ETI (N =3; ***p<0.001
vs. VEH). Data are represented as fold change of Nur77 mRNA levels
compared to controls (VEH) and normalized with GAPDH house keeping
transcript levels. Similar results were obtained using normalization with
the HPRT1 housekeeping gene (data not shown).
the striatum (Bardgett et al., 1993; Yamamoto and Cooperman,
1994).
Experiments using organotypic corticostriatal slices confirm
the direct modulation of Nur77 expression by mGlu5 and A2A
receptors, which is consistent with results obtained in the hip-
pocampus (Lindecke et al., 2006). In acute slice experiments, the
glutamate uptake inhibitor TBOA can induce changes in post-
synaptic currents (Beurrier et al., 2009) and quinpirole could
decrease excitatory postsynaptic potential triggered by TBOA and
low frequency cortical stimulation (Yin and Lovinger, 2006).
However, we were not able to modulate Nur77 mRNA levels
with quinpirole in our organotypic cultures (with or without
TBOA). This suggests that corticostriatal terminals might not
spontaneously release enough glutamate in our organotypic slice
preparations to record a presynaptic effect of the dopamine
D2 receptor agonist. In addition, direct D2 receptor activation
with quinpirole, or blockade by eticlopride, in organotypic cul-
tures also remained ineffective. This suggests that postsynaptic
D2 receptor activity is not associated with the modulation of
Nur77 expression in striatal cells. Thus, these results support an
indirect effect of D2 receptor drugs on striatal gene expression
(Figure 7).
The contribution of other presynaptic D2 heteroreceptors,
such as those located on striatal cholinergic interneurons (Yan
et al., 1997; Tozzi et al., 2011) is unlikely because we showed
that the muscarinic antagonist scopolamine administration did
not reduce eticlopride-induced Nur77 mRNA expression in the
striatum. On the contrary, scopolamine potentiated the effect of
eticlopride. This might reflect a prominent activity of this non-
selective muscarinic antagonist at m1–2 receptor subtypes located
on corticostriatal terminals, which can also modulate glutamate
release (Alcantara et al., 2001; Higley et al., 2009). The partic-
ipation of presynaptic D2 autoreceptors located on dopamine
terminals is unlikely as well. Indeed, an elegant study recently
showed that mice specifically lacking D2 autoreceptors (auto-
Drd2KO) display similar haloperidol-induced reduction of hor-
izontal locomotor activity compared to their littermate (Bello
et al., 2011), indicating that these receptors are not involved in
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FIGURE 7 | Suggested events leading to the modulation of striatal
gene transcription by a dopamine D2 antagonist.The figure includes a
schematic representation of a striatal medium spiny neuron (MSN) with a
glutamatergic terminal coming from the cortex. Data presented herein
suggest that the dopamine D2 antagonist blocks presynaptic D2
heteroreceptors (D2S) located on glutamatergic terminals, which control
glutamate release (step 1 and 2). This leads to an elevation of glutamate
contents in the synapse (step 3), which in turn activate postsynaptic
metabotropic mGlu5 and adenosine A2A receptors (step 4). Intracellular
signaling events associated with activation of mGlu5 receptors (in addition
to adenosine A2A receptors) then lead to the increase of Nur77 gene
transcription in MSNs (step 5). The dash line and question mark that link
postsynaptic D2L and A2A-mGlu5 receptors illustrate the fact that we were
unable to show a contribution of postsynaptic dopamine D2 receptors in the
transcriptional effect of mGlu5/A2A receptor agonists in our organotypic
slice preparations.
this D2 antagonist-induced effect. But, transcriptional activity of
haloperidol has not been investigated in this transgenic model.
Contribution of the dopamine D3 receptor, which is also a potent
target of eticlopride, can be discarded as well because haloperidol-
induced gene expression in the striatum is not altered in D3
receptor knockout mice (Robertson et al., 2004) and D3 receptor
specific antisense oligonucleotides, which significantly reduced D3
receptor binding site density, has been shown to reduce Nur77
expression (Tremblay et al., 1999). CB1 receptors can regulate
glutamate release from corticostriatal terminals (Gerdeman and
Lovinger, 2001; Kofalvi et al., 2005) and a D2-like-CB1 recep-
tor interplay has been observed in the striatum (Centonze et al.,
2004a). Thus, modulation of the present glutamate-dependent
effect of eticlopride by CB1 remains a possibility. Although we
showed that cannabinoid CB1 receptors antagonist AM251 did not
modulate eticlopride-induced striatal Nur77 mRNA expression
and that similar AM251 dosages can modulate dopamine-related
signaling (Kofalvi et al., 2005; Corbillé et al., 2007), we can-
not discard the possibility that a higher dose of AM251 might
have produced an effect. In addition, a contribution of other
receptor subtypes such as glutamate mGlu2/3 receptors (Garcia
et al., 2010), which can also modulate glutamate neurotransmis-
sion at corticostriatal terminals, or from thalamostriatal afferences
in the modulation of Nur77 expression in the striatal complex
cannot be excluded. Additional experiments will be required in
order to investigate the exact contribution of these receptor sub-
types and striatal afferents to D2 receptor antagonist-induced gene
transcription in selective striatal subterritories.
In conclusion, the present data indicates that mGlu5-A2A activ-
ities mediate D2 receptor antagonist effect on striatal gene expres-
sion (Figure 7). Our results provide new evidences that adenosine
and glutamate receptors might play an important role in typical
antipsychotic drug-mediated effects and uncover an unappreci-
ated role of presynaptic D2 heteroreceptors into the effect of
dopamine D2 receptor antagonists. In addition, these results sug-
gest that some striatal intracellular signaling events following D2
antagonist treatments might be attributed to metabotropic glu-
tamate and adenosine receptor activities instead of dopamine D2
receptors.
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